BRWM
KERX

B. Riley Wealth Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

B. Riley Wealth Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-350
Closed -$4K – 1109
2015
Q1 		$4K Hold
350
– – ﹤0.01% 907
2014
Q4 		$4K Hold
350
– – ﹤0.01% 892
2014
Q3 		$4K Hold
350
– – ﹤0.01% 940
2014
Q2 		$5K Hold
350
– – ﹤0.01% 947
2014
Q1 		$6K Buy
+350
New +$5.28K ﹤0.01% 871

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

B. Riley Wealth Management's KERX Position: Q2 2015 in Review

B. Riley Wealth Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2015, closing a stake of 350 shares — an estimated $4K sold.

B. Riley Wealth Management first reported a position in KERX in Q1 2014 and held it in 5 quarters. The position peaked at $6K in Q1 2014. 153 funds tracked by Wall St. Rank hold KERX as of Q2 2015.

  • B. Riley Wealth Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • B. Riley Wealth Management sold 350 Keryx Biopharmaceuticals Inc shares in Q2 2015, an estimated $4K.
  • B. Riley Wealth Management first reported a position in Keryx Biopharmaceuticals Inc in Q1 2014 and held it in 5 quarters.
  • B. Riley Wealth Management's Keryx Biopharmaceuticals Inc position peaked at $6K in Q1 2014.
  • 153 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2015.

Based on B. Riley Wealth Management's 13F filing for Q2 2015, filed 14 Jul 2015.